A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

January 18, 2017

Type of Cancer

Gastrointestinal

Site

Hackensack

Sponsor

Bristol-Myers Squibb

Protocol Number

CA209-577

To Learn More Call

(201)-510-0950